Nippon Kayaku Kabushiki Kaisha

Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai

Taiho Pharmaceutical Company Limited

Hiroo Hoshino

Nobuyoshi Shimada

Seiichi Saito

Tomio Takeuchi

Shinichi Kondo

Shigeru Hasegawa

Kenichi Matsubara

Yukihiro Nishiyama

Takemitsu Nagahata

Jun-ichi Seki

Katsutoshi Takahashi

Masayuki Kitagawa

Akio Fujii

Shuichi Gomi

Yoko Ikeda

Takayuki Tomizawa

Masa Hamada

Seiji Shibahara

Masakazu Fukushima

Akira Masuda

Akira Shiozawa

Hiroshi Yoshikawa

Yuh-ichiro Ichikawa

Kenji Kitazato

Katsuhiko Kurabayashi

Yuka Sugawara

Hiroshi Akaba

Haruo Machida

Junichi Seki

Kyoichi Shibuya

Rie Shinei

Kaoru Matsuo

Anti-HIV compositions

D-.beta.-lysylmethanediamine derivatives and preparation thereof

Pharmaceutical composition for inhibiting the infection with AIDS virus

A novel nucleic acid derivative represented by the following general formula (I) and physiologically acceptable salt thereof which are expected to have an antiviral activity: ##STR1## wherein B represents a nucleic acid base derivative; A.sup.1 and A.sup.2 represent, independently of each other, OR.sup.1 or OCOR.sup.1 ; R.sup.1 represents a hydrogen atom, a substituted or unsubstituted alkyl group or a substituted or unsubstituted aryl group; l represents a number of 0 or 1; and m and n each represents an integer of 0-2; provided that when l and m are 0, n is 0 or 2.

Adenine and guanine derivatives for the treatment of hepatitis virus

It was found that 2-halogeno-oxetanocin A and 4'-phosphate thereof represented by the following general formula (1): ##STR1## wherein X represents a halogen atom and R represents a hydrogen atom or a phosphoric acid residue ##STR2## or salts thereof exhibit a strong antiviral activity and are useful as an active ingredient of therapeutic drug for viral diseases. Further, it was also found that the compounds of this invention are characterized in that they are not inactivated by adenosine deaminase widely present in living bodies and exhibit a high residual activity.

2-halogeno-oxetanocin A and phosphoric ester thereof

This invention relates to novel oxetanocins represented by the following general formula (I): ##STR1## wherein R represents a group represented by ##STR2## and their pharmacologically acceptable salts which have antiviral activities.

Oxetanocins

The present invention relates to phosphoric acid esters of oxetanocins having an antiviral activity which are represented by general formula (I): ##STR1## wherein R.sub.1 represents a phosphoric acid ester residue, X represents hydrogen, hydroxy or hydroxymethyl group, and B represents a purine base residue, and pharmacologically acceptable salts thereof.

Antiviral phosphoric acid esters of oxetanocins

Pharmaceutical compositions containing at least one of benanomicins A and B and their salts are now provided, which are useful to inhibit the infection of human T-cells with HIV, namely a virus causative of acquired human immunodeficiency syndrome (AIDS). Thus, benanomicins A and B as well as their salts are useful as antiviral agent against HIV.

Pharmaceutical composition for inhibiting infection with virus causative

As a new compound is now provided N-acetylbenanomicin B which is useful as an antifungal agent and also as antiviral agent for inhibiting infection of human T-cell with HIV, namely a virus causative of acquired human immunodeficiency syndrome. N-acetylbenanomicin B may be prepared by acetylation of 4'-amino group of benanomicin B which is fermentatively produced by a new microorganism, MH193-16F4 strain of actinomycetes.

Antibiotic N-acetylbenanomicin B, and the production and uses thereof

This invention relates to oxetanocin-related compounds represented by the following formula (I): ##STR1## [in formula (I), R.sub.1, Y and B have the following meanings: (a) R.sub.1 represents --CH.sub.2 OH or --CH.sub.2 OCO-(alkyl),

Oxetanocin-related compounds and pharmaceutical compositions containing

Oxetanocin derivatives represented by formula: ##STR1## wherein X represents H or ##STR2## or a pharmacologically acceptable salt thereof exhibit an anti-viral activity. Anti-viral compositions comprising the oxetanocin derivatives or their pharmacologically acceptable salts as the effective ingredient are also provided.

Oxetanocin derivatives and their salts as well as use thereof

A pharmaceutical composition for inhibiting Human Immunodeficiency Virus (HIV), which is characterized by comprising a compound represented by the formula (1) ##STR1## or a pharmaceutically acceptable salt thereof as an active ingredient.

Method for inhibiting HIV and an pharmaceutical composition therefor

The present invention relates to a novel compound having hypoxanthine base represented by the following formula: ##STR1## as well as to use of said compound and process for producing said compound. The novel compound of the present invention has an immunosuppressive and antiviral actions and is expected to be useful as a medical drug.

Purine derivative

Growing community of inventors

Maebashi, Japan

Hiroo Hoshino